MicroScale system integrating Patient-specific cancer Organoids in a 3D Tumor microenvironment for Therapy rEsponse preDiction

SPOTTED develops patient-derived 3D models of pancreatic cancer using microfluidics to enhance personalized therapy through precise drug screening and real-time analysis.

Subsidie
€ 150.000
2025

Projectdetails

Introduction

Cancer remains a leading global cause of death, with incidence projected to increase significantly by 2050. Despite advances in detection and treatment, there is an urgent need for more effective and personalized therapies.

Personalized Medicine

Personalized medicine (PM) is emerging as the future of cancer care, using 3D patient-specific models to replicate the tumor's complexity. Current in vitro models struggle to accurately mimic the tumor microenvironment (TME), including the extracellular matrix (ECM) and stromal interactions, which are critical to tumor progression and therapy response.

Project Overview

SPOTTED aims to address these limitations by developing patient-derived (PD) in vitro models integrated into a microfluidic device. This is achieved by exploiting patient-derived organoids (PDOs) from bioptic tissues from the Biobanca di Ricerca of the University Hospital of Padua.

Case Study

The first vertical case study is on pancreatic cancer (PC), projected to become the second deadliest type of solid tumor by 2040. Our SPOTTED platform will use PDOs and PD-ECM hydrogels to reconstruct a realistic 3D model of PC, incorporating stromal and immune cells.

Methodology

By replicating the TME, SPOTTED enables precise drug screening and therapeutic testing in a highly controlled and automated environment. Its design allows for:

  • Real-time monitoring and analysis
  • Scalable, reproducible experiments tailored to individual patients

Conclusion

SPOTTED, with its customizable, patient-specific approach, aims to bridge the gap between laboratory research and clinical application. This paves the way for more effective, tailored therapies for PC and other solid tumors, with the potential to revolutionize personalized cancer treatment.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 150.000
Totale projectbegroting€ 150.000

Tijdlijn

Startdatum1-6-2025
Einddatum30-11-2026
Subsidiejaar2025

Partners & Locaties

Projectpartners

  • UNIVERSITA DEGLI STUDI DI PADOVApenvoerder

Land(en)

Italy

Vergelijkbare projecten binnen European Research Council

ERC Proof of...

Development of a high-throughput microplate based device to analyse the patient derived tumour microenvironment

3DTUMOUR aims to enhance drug development success by providing patient-specific 3D bioprinted tumour models for ex vivo testing, improving treatment efficacy and reducing toxicity in cancer therapy.

€ 150.000
ERC Starting...

Personalised Mechanobiological Models to Predict Tumour Growth and Anti-Cancer Drug Penetration

This project aims to develop a personalized cancer treatment framework by modeling stress-dependent tumor growth and drug penetration to enhance patient-specific therapy outcomes.

€ 1.499.693
ERC Starting...

Capturing tumoral drug metabolism by Cells In the Tissue Environment using spatial pharmacometabolomics

The CITE project aims to develop innovative analytical technologies to study intratumoral drug metabolism in pancreatic cancer, enhancing understanding of treatment resistance mechanisms.

€ 2.481.640
ERC Proof of...

Advanced 3D in vitro models based on magnetically-driven docking of modular microscaffolds

This project aims to develop 3D modular co-culture systems using magnetic microscaffolds to replicate brain tumor microenvironments for drug screening and cancer therapy testing.

€ 150.000
ERC Proof of...

Cell-instructive matrices to deconstruct tumour tissues

The project aims to develop a controllable platform for patient-specific pancreatic cancer models to discover improved therapies targeting tumor biology and cell interactions.

€ 150.000

Vergelijkbare projecten uit andere regelingen

EIC Accelerator

Multi-organ toxicity and efficacy test platform for Personalized medicine & Drug development

Cherry Biotech aims to revolutionize drug development and personalized medicine by providing a patented 3D cell culture platform that enhances predictability and reduces reliance on animal testing.

€ 2.499.831
EIC Pathfinder

A multiplexed biomimetic imaging platform for assessing single cell plasticity (Plastomics) and scoring of tumour malignancy

The PLAST_CELL project aims to develop a microfluidics-based imaging platform to quantify cancer cell plasticity, enhancing diagnosis and treatment of metastasis and therapy resistance.

€ 2.982.792
EIC Transition

Next-Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Develop a drug discovery platform using patient-derived organoids and machine learning to target stem cell signaling pathways in colorectal cancer, aiming to improve treatment outcomes.

€ 2.433.125
EIC Transition

Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid Tumours

ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.

€ 2.499.911
EIC Pathfinder

3D spheroids derived from single cells for discovering stochastic patterns behind metastasis

3DSecret aims to revolutionize cancer treatment by analyzing single circulating tumor cells using advanced technologies to uncover stochastic patterns driving metastasis and improve diagnosis and prognosis.

€ 2.591.050